Revenue growth slipped into the red in Q2 as temporary closures of clinics and postponements of non-acute surgical treatments weighed on the Ophthalmic Devices segment. While the cash-cow Microsurgery segment managed to stay in the black, it couldn’t prevent significant erosion in the operating margin, which was further pressurised by higher R&D spend. Q3 has got off to a weak start, nevertheless, if the early encouraging signs seen in China are visible in the US and Europe, Q4 coul
12 May 2020
Q2 impacted by postponement of elective procedures
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 impacted by postponement of elective procedures
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
12 May 2020 -
Author:
Sumit Sayal -
Pages:
3
Revenue growth slipped into the red in Q2 as temporary closures of clinics and postponements of non-acute surgical treatments weighed on the Ophthalmic Devices segment. While the cash-cow Microsurgery segment managed to stay in the black, it couldn’t prevent significant erosion in the operating margin, which was further pressurised by higher R&D spend. Q3 has got off to a weak start, nevertheless, if the early encouraging signs seen in China are visible in the US and Europe, Q4 coul